pracinostat

Small moleculeexperimental

Pracinostat (SB939) is an orally bioavailable, small-molecule histone deacetylase (HDAC) inhibitor based on hydroxamic acid with potential anti-tumor activity characterized by favorable physicochemical, pharmaceutical, and pharmacokinetic properties. — Wikipedia

Clinical trial activity

16 trials · 17 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
9
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2007 (NCT00741234)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCCCc1nc2cc(/C=C/C(=O)NO)ccc2n1CCN(CC)CC
Mol. weight
358.49 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 3-(2-butyl-1-(2-diethylaminoethyl)-1h-benzoimidazol-5-yl)-n-hydroxyacrylamide-hydrochloride
  • pracinostat
  • pracinostat
  • pracinostat
  • pracinostat
  • sb939
  • sb939
  • sb939 compound

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03848754Phase 1May 24, 2019Medical College of Wisconsin
NCT03495934Phase 1Feb 8, 2018Helsinn, Quotient
NCT03151408Phase 3Jun 1, 2017Clinipace LTD, Helsinn, University of Texas at Houston
NCT03151304Phase 2Jun 1, 2017Helsinn, MEI Pharma, University of Texas at Houston
NCT02267278Phase 2Jan 12, 2015MEI Pharma, University of Texas at Houston
NCT02118909Phase 1May 1, 2014Celerion, Helsinn
NCT02058784Early Phase 1 (Phase 1)Feb 1, 2014Celerion, Helsinn
NCT01993641Phase 2Dec 1, 2013Helsinn, University of Texas at Houston
NCT01912274Phase 2Oct 1, 2013Helsinn, University of Texas at Houston
NCT01873703Phase 2Jun 1, 2013Helsinn, University of Texas at Houston
NCT01200498Phase 2Nov 1, 2010S*BIO, University of Texas at Houston
NCT01184274Phase 1Sep 1, 2010Canadian Cancer Trials Group, University of Toronto
NCT01112384Phase 2Mar 1, 2010Canadian Cancer Trials Group, University of Alberta
NCT01075308Phase 2Feb 1, 2010British Columbia Cancer Agency, Canadian Cancer Trials Group, University of Calgary
NCT00504296Phase 1Jun 1, 2007Canadian Cancer Trials Group, University of Toronto
NCT00741234Phase 1Apr 1, 2007National University of Singapore, S*BIO, Singapore General Hospital, The National Cancer Center, University of Texas at Houston, University of Wisconsin
Showing 16 of 16 trials
Page 1 / 1

Organizations

Research & Development (17)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
HelsinnFor profit8832013
University of Texas at HoustonAcademic/Hospital8232007
Canadian Cancer Trials GroupAcademic/Hospital4422007
CelerionFor profit2012014
MEI PharmaFor profit2012015
S*BIOFor profit2122007
University of TorontoAcademic/Hospital2012007
British Columbia Cancer AgencyAcademic/Hospital1012010
Clinipace LTDFor profit1012017
Medical College of WisconsinAcademic/Hospital1112019
National University of SingaporeAcademic/Hospital1012007
QuotientFor profit1012018
Singapore General HospitalAcademic/Hospital1012007
The National Cancer CenterAcademic/Hospital1012007
University of AlbertaAcademic/Hospital1012010
University of CalgaryAcademic/Hospital1012010
University of WisconsinAcademic/Hospital1012007
17 organizations
Page 1 / 1